S1416 trial results show PARP inhibitor benefit in "BRCA-like" triple-negative breast cancer

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

Clinical trials in adults conducted within the National Cancer Institute’s National Clinical Trials Network over the last four decades are estimated to have extended the lives of patients with cancer in the U.S. by at least 14.2 million life-years, at an estimated cost of only $326 per life-year added

The E1910 study showed that, after about 3.5 years of follow-up, 83% of patients who went on to receive additional standard consolidation chemotherapy plus experimental blinatumomab were alive versus 65% of those who received chemotherapy only

NRG Oncology recently announced the appointed leadership of the organization’s new Diversity, Equity, and Inclusion Committee; the group also announced a change in the leadership of their Ancillary Projects Committee

The use of a simplified treatment regimen by oncologists, along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts, resulted in a dramatic decrease in early deaths from acute promyelocytic leukemia

With 12 years of follow-up, an updated analysis from the TAILORx trial confirms the original findings that chemotherapy has no benefit for a large proportion of women with early-stage breast cancer

Patients with high-risk melanoma had better quality of life on adjuvant pembrolizumab than on standard adjuvant immunotherapy

SWOG researchers will present 10 abstracts at this year's San Antonio Breast Cancer Symposium, including results from S1207, S1714, and S1007 (RxPONDER), as well as an analysis of ER use by insurance status